Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Proline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 3/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.41 |
| ▸ | NOS2 | P35228 | 2/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.38 |
| ▸ | ARG1 | P05089 | 1/20 | 0.38 |
| ▸ | SCN4A | P35499 | 1/20 | 0.37 |
| ▸ | FAP | Q12884 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Proline SCHEMBL719217 | 1.00 | PRCP (0.46) | PRCPMEN1BLMKMT2ADPP4 | |
| Proline SCHEMBL3266120 | 0.92 | MEN1 (0.45) | PRCPMEN1BLMKMT2ADPP4 | |
| Proline SCHEMBL3266119 | 0.92 | MEN1 (0.45) | PRCPMEN1BLMKMT2ADPP4 | |
| Proline SCHEMBL10980264 | 0.90 | NOS2 (0.44) | PRCPMEN1BLMKMT2ADPP4 | |
| Proline SCHEMBL7143088 | 0.88 | MEN1 (0.42) | PRCPMEN1BLMKMT2ADPP4 | |
| Proline SCHEMBL28049461 | 0.87 | MEN1 (0.48) | PRCPMEN1BLMKMT2ADPP4 | |
| Proline SCHEMBL10141185 | 0.87 | — | — | |
| Proline SCHEMBL462226 | 0.87 | BLM (0.52) | PRCPMEN1BLMKMT2ADPP4 | |
| Proline SCHEMBL718906 | 0.87 | BLM (0.52) | PRCPMEN1BLMKMT2ADPP4 | |
| D-Proline SCHEMBL21462052 | 0.87 | BLM (0.52) | PRCPMEN1BLMKMT2ADPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180256717-A1 | PROTEIN COMPOSITIONS AND USE THEREOF | DRUG DISCOVERY LABORATORY AS (NO) | 2018-09-13 | — | — | US | disclosed |
| EP-3236942-A1 | PROTEIN COMPOSITIONS AND USE THEREOF | Drug Discovery Laboratory AS (NO) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016103034-A1 | PROTEIN COMPOSITIONS AND USE THEREOF | DRUG DISCOVERY LABORATORY AS (NO) | 2016-06-30 | — | — | WO | disclosed |
| US-8124584-B2 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20090304629-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | MIAO ZHENWEI | 2009-12-10 | — | — | US | disclosed |
| US-7601709-B2 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| EP-1590442-A4 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARM INC (US) | 2007-07-18 | — | — | EP | disclosed |
| EP-1590442-A3 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2005-11-03 | — | — | EP | disclosed |
| EP-1590442-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20050153877-A1 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| WO-2004072243-A2 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2004-08-26 | — | — | WO | disclosed |
| US-5614615-A | Sialyl Lewis X mimetics incorporating fucopeptides | THE SCRIPPS RESEARCH INSTITUTE (US) | 1997-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153877-A1 | Macrocyclic hepatitis C serine protease inhibitors | PRSS1, SPINT2, TMPRSS4 | PRCP 33/4885MEN1 4037/4885BLM 3449/4885 |
| US-20090304629-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, TMPRSS4 | PRCP 33/4885MEN1 4019/4885BLM 3450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.